ceruletide and Intestinal-Diseases

A double-blind and randomized clinical trial, which included 48 patients with postoperative intestinal paralysis on the third day after laparotomy, demonstrated no difference between treatment with ceruletide (0.3 microgram/kg body weight) and neostigmine (5.0 micrograms/kg body weight) in restoring normal intestinal function.

Topics: Adolescent; Adult; Aged; Ceruletide; Clinical Trials as Topic; Double-Blind Method; Humans; Intestinal Diseases; Middle Aged; Neostigmine; Paralysis; Postoperative Complications

Topics: Abdomen; Adult; Aged; Ceruletide; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Intestinal Diseases; Male; Middle Aged; Peristalsis; Postoperative Complications; Random Allocation

Acute pancreatitis (AP) is a common acute abdominal condition, frequently associated with intestinal barrier dysfunction, which aggravates AP retroactively. Butyrate exhibits anti-inflammatory effects in a variety of inflammatory diseases. However, its potential beneficial effect on AP and the underlying mechanisms have not been investigated.. Experimental AP was induced by caerulein hyperstimulation in wild-type and GPR109A. Butyrate prophylaxis attenuated AP as shown by reduced serum amylase and lipase levels, pancreatic oedema, myeloperoxidase activity, and improved pancreatic morphology. Amelioration of pancreatic damage by butyrate was associated with reduced levels of TNF-α, IL-6, and CCL2 and suppressed activation of the NLRP3 inflammasome in both pancreas and colon. Further, butyrate ameliorated pancreatic inflammation by suppressing interactions between histone deacetylase 1 (HDAC1) and AP1 and STAT1 with increased histone acetylation at H3K9, H3K14, H3K18, and H3K27 loci, resulting in suppression of NLRP3 inflammasome activation and modulation of immune cell infiltration in pancreas. Additionally, butyrate mediated STAT1/AP1-NLRP3 inflammasome suppression via HDAC1 inhibition was demonstrated in peritoneal macrophage. In colon, butyrate inhibited NLRP3 inflammasome activation via GPR109A. Accordingly, the modulatory effects of butyrate on AP, AP-associated gut dysfunction, and NLRP3 inflammasome activation were diminished in GPR109A. Our study dissected tissue-specific anti-inflammatory mechanisms of butyrate during AP, suggesting that increased colonic levels of butyrate may be a strategy to protect against AP.

Topics: Acute Disease; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Butyrates; Ceruletide; Female; Intestinal Diseases; Intestine, Small; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Pancreas; Pancreatitis

Topics: Ceruletide; Humans; Intestinal Diseases; Intestinal Obstruction; Postoperative Complications

The effect of caerulein upon postoperative enteral paralysis was investigated in animals and men. The increase in motility effected by cerulein in rats was proved by the increase in passage demonstrated after administration of radioactive test food (51CrO4Na2 solution). A clinical survey comprising 20 patients in the postoperative period following cholecystectomy, compared to an untreated control group, confirmed our findings.

Topics: Animals; Ceruletide; Cholecystectomy; Gastrointestinal Motility; Humans; Intestinal Diseases; Muscle Tonus; Paralysis; Rats

Topics: Adult; Aged; Ceruletide; Female; Gastrointestinal Motility; Humans; Intestinal Diseases; Male; Middle Aged; Postoperative Complications